NPSP NPS Pharmaceutical Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NPSP NPS Pharmaceutical

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (36)	12/16/1999 9:58:00 AM
From: biowa	Read Replies (1) of 363

Rick, <<not saying that I didn't want to hear more about R&D and how it might graduate to preclinical...... need to do lots of homework to comment further>> As I was hoping you would; you know neuro much better than I do. Actually on the cash front, if they can get their burn down to the 10-12M US$ they quoted in the original release, then they should have slightly over 2 years burn. AMGN/Kirin is paying for the HPT calcimimetics clinical development and it looks like the Canadian government is going to pay for at least part of the ALX-0600 clinical development. Would have to double-check what Smith-Kline's funding is for the osteoporosis, don't know if they'll also pick up ALX 1-11. Checking quickly, it looks like Smith-Kline will pay for clinical development (they are currently partially funding pre-clinical), don't know if/how that changes if NPS elects their co-promote option. biowa

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next